Insights from 2023 ASH Annual Meeting

 

Lymphoma
06:43

Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of MCL - Highlights & Key Takeaways"

FEATURING Victor Yazbeck
  • 171 views
  • January 24, 2024
  • 1
11:40

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "The European MCL Network R2 Elderly Trial - R2 vs. R Maintenance After 1L Chemoimmunotherapy in Elderly MCL Patients"

FEATURING Vincent Ribrag
  • 41 views
  • January 16, 2024
08:29

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "CAR T-Cell Therapy in Aggressive Lymphomas - Identifying Prognostic and Predictive Markers"

FEATURING Anna Sureda
  • 74 views
  • January 8, 2024
05:12

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Results From ELM-2, a Ph 2 Study of Odronextamab in Pts With R/R FL"

FEATURING Jose C. Villasboas
  • 59 views
  • December 29, 2023
08:30

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "PD-1 Blockade Before AutoSCT in R/R Classic Hodgkin Lymphoma"

FEATURING Sanjal Desai
  • 92 views
  • December 29, 2023
  • 1
11:11

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Ibrutinib and Venetoclax in Symptomatic, Treatment-Naïve Patients With Waldenstrom Macroglobulinemia"

FEATURING Jorge Castillo
  • 118 views
  • December 29, 2023
09:27

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Ph2 EpiRCHOP Study - Tazemetostat With R-CHOP in Elderly 1L DLBCL"

FEATURING Clementine Sarkozy
  • 106 views
  • December 28, 2023
09:10

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Acalabrutinib Added to Lenalidomide & Rituximab in Pts With Untreated Advanced Phase FL"

FEATURING Paolo Strati
  • 71 views
  • December 22, 2023
06:00

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Effectiveness of CIT and Novel Therapies in 2L+ Therapy for Pts With R/R Aggressive LBCL"

FEATURING Loretta Nastoupil
  • 107 views
  • December 22, 2023
09:05

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Time-Limited Exposure to a ROR1-Targeting Bispecific T-Cell Engager (NVG-111) Subjects With R/R CLL and MCL"

FEATURING Parag Jasani
  • 37 views
  • December 22, 2023
06:09

Insights from 2023 ASH Annual Meeting

CLL/SLL: Outcomes of Pts With Richter's Transformation Without Prior Chemoimmunotherapy

FEATURING Adam Kittai
  • 357 views
  • December 22, 2023
05:45

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Anti-CD19 CAR T-Cell Therapy for Richter's Transformation"

FEATURING Adam Kittai
  • 49 views
  • December 22, 2023
13:38

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "S1826 Trial - Nivo-AVD Compared to Brentuximab Vedotin-AVD in Pediatric Advanced Stage cHL"

FEATURING Sharon Castellino
  • 34 views
  • December 21, 2023
02:27

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Efficacy of Mosunetuzumab Monotherapy in Patients With R/R Richter's Transformation"

FEATURING Chan Cheah
  • 68 views
  • December 20, 2023
02:26

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Obinutuzumab, Lenalidomide, and Venetoclax in Patients With Treatment-Naïve Advanced Stage Follicular Lymphoma"

FEATURING Chan Cheah
  • 48 views
  • December 20, 2023
10:19

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Final Analysis of the ELM-2 Study - Odronextamab in Patients With R/R DLBCL"

FEATURING Sabarish Ayyappan
  • 129 views
  • December 20, 2023
10:57

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Mosunetuzumab + Polatuzumab Vedotin in Pts With R/R LBCL"

FEATURING Elizabeth Budde
  • 132 views
  • December 20, 2023
13:46

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Smart Stop Trial - Lenalidomide, Tafasitamab, Rituximab, & Acalabrutinib Alone and With Combination Chemo for 1L DLBCL"

FEATURING Jason Westin
  • 186 views
  • December 20, 2023
  • 2
30:24

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Treatment of Older Patients With HL in the Modern Era"

FEATURING Andrew Evens
  • 153 views
  • December 19, 2023
  • 2
10:58

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "ViPOR Trial - Multi-Targeted Therapy With Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide R/R DLBCL"

FEATURING Christopher J. Melani
  • 60 views
  • December 19, 2023
11:05

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Alliance A051301/BMT-CTN 1201 Study - Ibrutinib + Standard Conditioning and as Consolidation After AutoHCT for R/R ABC-DLBCL"

FEATURING Charalambos Andreadis
  • 41 views
  • December 19, 2023
06:30

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Pirtobrutinib in R/R FL - Results From the Ph1/2 BRUIN Study"

FEATURING Nirav Shah
  • 68 views
  • December 18, 2023
11:11

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prognostic Utility of MRD After Curative Intent Induction Therapy for DLBCL - A Prospective Real-World ctDNA Study"

FEATURING Brian Sworder
  • 133 views
  • December 18, 2023
  • 1
08:59

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "SWOG S1826 Trial - Nivo-AVD vs. Bv-AVD in Older Patients (Aged 60+ Years) With Advanced Stage HL"

FEATURING Sarah Rutherford
  • 206 views
  • December 18, 2023
  • 1
11:43

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Selection of Bispecific Antibody Therapies or CAR T-Cell Therapy in Relapsed Lymphomas"

FEATURING Manali Kamdar
  • 177 views
  • December 17, 2023
  • 1
16:09

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Addition of Inotuzumab Ozogamicin to the Conditioning Regimen of allo-SCT for R/R CD22+ Lymphoid Malignancies"

FEATURING Issa Khouri
  • 27 views
  • December 17, 2023
10:21

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "EOT Response Assessment After 1L Tx For Aggressive B-Cell Lymphoma - Singular PET/CT Scan vs. Ultrasensitive ctDNA"

FEATURING Mark Roschewski
  • 82 views
  • December 17, 2023
  • 1
13:06

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "ECOG-ACRIN E4412 Study of Ipi, Nivo, and Brentuximab Vedotin in Pts With R/R cHL"

FEATURING Catherine Diefenbach
  • 24 views
  • December 17, 2023
18:05

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Optimal Management of R/R cHL - Post-Brentuximab & Checkpoint Inhibitor Failure"

FEATURING Natalie Grover
  • 25 views
  • December 15, 2023
09:56

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Limited Duration Loncastuximab Tesirine With Rituximab in High-Risk R/R Follicular Lymphoma"

FEATURING Juan Pablo Alderuccio
  • 54 views
  • December 15, 2023
  • 1
11:42

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Impact of Large Cells and Ki-67% on Outcomes in Patients With Newly Diagnosed MZL"

FEATURING Narendranath Epperla
  • 84 views
  • December 15, 2023
04:34

Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "Highlights and Key Takeaways in MCL"

FEATURING Preetesh Jain
  • 196 views
  • December 15, 2023
05:10

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Efficacy of Double Step-Up Dosing of AZD0486, a Novel CD19xCD3 T-Cell Engager, in Subjects With R/R B-NHL"

FEATURING Sameh Gaballa
  • 93 views
  • December 15, 2023
05:41

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Acalabrutinib With Rituximab as 1L Therapy for Older Patients With MCL - Results of a Ph2 Study"

FEATURING Preetesh Jain
  • 48 views
  • December 14, 2023
04:56

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Immune Reconstitution and Infection Patterns Following CAR T-Cell Therapy in Patients With Aggressive Lymphoma"

FEATURING Megan Melody
  • 115 views
  • December 14, 2023
  • 1
10:28

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Multicenter Study of MCL Outcomes Following 1L BR and 2L BTKi Therapy"

FEATURING Yucai Wang
  • 60 views
  • December 13, 2023